This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kawagoe, H. Articles by Grosveld, G. C. Search for Related Content PubMed PubMed Citation Articles by Kawagoe, H. Articles by Grosveld, G. C.

TEL2, an ETS Factor Expressed in Human Leukemia, Regulates Monocytic Differentiation of U937 Cells and Blocks the Inhibitory Effect of TEL1 on Ras-Induced Cellular Transformation

Department of Genetics, St. Jude Children’s Research Hospital, Memphis, Tennessee

TEL2 is a member of the ETS family of transcription factors, which is highly similar to TEL1/ETV6. It binds to DNA via the ETS domain and interacts with itself or TEL1 via the pointed domain. The expression of TEL2 in normal and leukemic hematopoietic cells suggests a role in hematopoietic development. In this article, we describe the role of TEL2 in hematopoietic differentiation and cellular transformation. Quantitative reverse transcription-PCR showed that the expression of TEL2 mRNA was down-regulated during monocytic differentiation of U937 and HL60 induced by 1,25-(OH)₂ vitamin D₃ and 12-O-tetradecanoylphorbol 13-acetate, respectively. Overexpression of TEL2 in U937 cells inhibited differentiation induced by vitamin D₃. In contrast, overexpression of a TEL2 mutant lacking either the pointed domain or a functional ETS domain induced both differentiation of U937 cells and inhibited their growth in vitro and in vivo. In addition, these mutants blocked TEL2-mediated transcriptional repression of a synthetic promoter containing TEL2 binding sites. These data suggest that dominant-negative inhibition of TEL2 might cause differentiation. Quantitative reverse transcription-PCR demonstrated that TEL2 is expressed at higher level in some primary human leukemia samples than in normal bone marrow. Furthermore, overexpression of TEL2 in NIH3T3-UCLA cells blocked the inhibitory effect of TEL1 on Ras-induced cellular transformation. These results suggest that TEL2 may play an important role in hematopoiesis and oncogenesis.

This article has been cited by other articles:

				H. Kawagoe, A. Kandilci, T. A. Kranenburg, and G. C. Grosveld Overexpression of N-Myc Rapidly Causes Acute Myeloid Leukemia in Mice Cancer Res., November 15, 2007; 67(22): 10677 - 10685. [Abstract] [Full Text] [PDF]

				C. Carella, M. Potter, J. Bonten, J. E. Rehg, G. Neale, and G. C. Grosveld The ETS factor TEL2 is a hematopoietic oncoprotein Blood, February 1, 2006; 107(3): 1124 - 1132. [Abstract] [Full Text] [PDF]

				H. Kawagoe and G. C. Grosveld Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9 Blood, December 15, 2005; 106(13): 4269 - 4277. [Abstract] [Full Text] [PDF]

				H. Kawagoe and G. C. Grosveld MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice Blood, December 15, 2005; 106(13): 4278 - 4286. [Abstract] [Full Text] [PDF]

				M. Cardone, A. Kandilci, C. Carella, J. A. Nilsson, J. A. Brennan, S. Sirma, U. Ozbek, K. Boyd, J. L. Cleveland, and G. C. Grosveld The Novel ETS Factor TEL2 Cooperates with Myc in B Lymphomagenesis Mol. Cell. Biol., March 15, 2005; 25(6): 2395 - 2405. [Abstract] [Full Text] [PDF]